WeVote
Log In

Bill

Bill

HF 1807

Nonopioid drugs coverage required for treatment or management of pain.

2025-2026 Regular Session Introduced by Dave Baker and 2 co-sponsors

Requires health plans to cover nonopioid drugs for treating or managing pain, expanding access to nonopioid options for pain relief.

Introduction and first reading, referred to Health Finance and Policy
#drugsandmedicine #healthandhealthdepartment
0
WeVote Research Nonpartisan
Bill Summary · HF 1807

Summary of HF 1807 (Minnesota)

Overview

  • Bill number: HF 1807
  • Title: Nonopioid drugs coverage required for treatment or management of pain
  • Status: Introduction and first reading; referred to Health Finance and Policy
  • Introduced: March 3, 2025
  • Classification/Subject: Bill; Drugs and Medicine, Health and Health Department
  • Related bill: SF 1947 (companion)

HF 1807 would require health plans to cover nonopioid drugs used for the treatment or management of pain. The bill’s title indicates a policy goal of expanding access to nonopioid pharmacological options for pain relief, which may be part of broader efforts to reduce reliance on opioid therapies.

What the bill would do (high-level)

  • Mandate coverage by health plans for nonopioid medications specifically used to treat or manage pain.
  • The text provided does not specify which drugs are included, the level of coverage (e.g., formulary placement, cost-sharing), exemptions, or any timelines beyond the introduction and referral.
  • The bill name suggests an emphasis on nonopioid pharmacological options, potentially alongside existing pain management approaches.

Who would be affected

  • Health plans/insurers: Likely required to cover nonopioid analgesic medications for pain management under the plan terms.
  • Patients/consumers: Individuals seeking pain relief with nonopioid medications could experience improved access and potential changes in out-of-pocket costs, depending on plan design.
  • Healthcare providers: Clinicians prescribing nonopioid analgesics may see easier reimbursement and fewer barriers to offering nonopioid options.

Procedural and timeline aspects

  • Introduced: March 3, 2025, during the 2025 session.
  • Status: First reading; referred to the House Committee on Health Finance and Policy.
  • Companion bill: SF 1947 (Minnesota Senate), indicating parallel consideration in a companion chamber.

Potential implications and questions (based on the available information)

  • How broadly the term “nonopioid drugs” is defined (which medications are included, and whether certain exceptions apply).
  • Whether the bill specifies thresholds for coverage, formulary requirements, prior authorization, rider or cost-sharing protections, or exemptions for small employers.
  • Any fiscal impact on state programs or private insurers, and how premiums or plan costs might be affected.
  • Next steps in committee analysis, potential amendments, and ultimate passage decisions.

Next steps for readers

  • Monitor the bill’s progress in the House Health Finance and Policy committee and note any amendments.
  • Review the companion SF 1947 for parallel language and potential Senate actions.
  • Await the full text to understand specific definitions, coverage standards, exemptions, and enforcement mechanisms.

This summary reflects the information available from the bill’s introduction and does not include provisions not yet released in the public record.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.